Pemirolast ophthalmic - Santen

Drug Profile

Pemirolast ophthalmic - Santen

Alternative Names: Alamast; Alegysal; BMY 26517; DE 068; Pemilaston; Pemirolast ophthalmic; Pemirolast potassium

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb; Mitsubishi Tanabe Pharma Corporation
  • Class Antiallergics; Antiasthmatics; Nonsteroidal anti-inflammatories; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Allergic conjunctivitis; Seasonal allergic rhinitis

Most Recent Events

  • 07 Mar 2011 Mitsubishi Tanabe Pharma Corporation transfers marketing rights of Alegysal® to its subsidiary, Tanabe Seiyaku Hanbai
  • 24 May 2004 Launched for Allergic conjunctivitis in China (Ophthalmic)
  • 24 May 2004 Launched for Allergic conjunctivitis in Philippines (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top